MedTrace Logo

Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake

NCT06072365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-10-10

No results posted yet for this study

Summary

The aim of the study is to describe the evolution of caloric intake in patients with cystic fibrosis with an indication to start treatment with Elexacaftor/Tezacaftor/Ivacaftor according to the Marketing Authorization, between the start of treatment and at 12 months.

Conditions

Interventions

OTHER

nutritional intake questionnaire

patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Marion LAGARRIGUE · University Hospital, Toulouse

Eligibility

Min Age
2 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2022-09-23
Completion
2023-01-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06072365 on ClinicalTrials.gov